What is the drug of choice (DOC) for the treatment of subacute sclerosing panencephalitis (SSPE)?
What is the recommended regimen for post-exposure prophylaxis for HIV?
In areas with chloroquine-sensitive P. vivax, what is the preferred drug for treating the blood stages?
What is the Hib conjugate vaccine made of?
Which of the following medications is not indicated for the treatment or prophylaxis of seasonal influenza?
Which of the following is not true about the Vi polysaccharide vaccine for typhoid?
Which statement is true regarding the influenza vaccine?
Quinine primarily acts on which stage of the Plasmodium life cycle?
Which antitubercular drug makes the patient non-infective the earliest?
Thymidine is responsible for resistance to which antibiotic ?
Explanation: ***Inosine pranobex*** - **Inosine pranobex (Isoprinosine)** is considered the **oral drug of choice** for treating **subacute sclerosing panencephalitis (SSPE)**, particularly in the early stages, as it has shown success in delaying disease progression. - This drug works by **modulating the immune system** and enhancing T-cell function, which helps control the persistent measles virus infection in the CNS. - **Note:** Best outcomes are achieved when inosine pranobex is combined with **intrathecal/intraventricular interferon-alpha**, but as a single oral agent, inosine pranobex is the primary choice. *Abacavir* - **Abacavir** is an **antiretroviral drug (NRTI)** used in the treatment of **HIV infection**. - It inhibits reverse transcriptase and has **no role** in treating measles virus-induced SSPE. *Glatiramer* - **Glatiramer acetate** is an **immunomodulatory drug** used in **multiple sclerosis (MS)**. - It works by mimicking **myelin basic protein** to reduce immune attacks on myelin, but is **not effective** against viral infections like SSPE. *Interferon* - **Interferon-alpha** (particularly **intrathecal/intraventricular** administration) has been used in **SSPE** as **combination therapy** with inosine pranobex, showing improved outcomes. - However, when given systemically alone, it has **significant side effects** and **variable efficacy**. - As a single answer option without specifying the route, **inosine pranobex** is preferred as the primary oral DOC.
Explanation: ***Tenofovir disoproxil fumarate + Emtricitabine + Dolutegravir for 28 days*** - This is the **current first-line recommended regimen** for **HIV post-exposure prophylaxis (PEP)** according to WHO (2021), CDC, and Indian NACO guidelines. - It includes two **nucleoside reverse transcriptase inhibitors (NRTIs)** and an **integrase strand transfer inhibitor (INSTI)**. - **Dolutegravir** is preferred over Raltegravir due to **superior efficacy, better tolerability, higher barrier to resistance, once-daily dosing**, and fewer drug interactions. - The duration of **28 days** is crucial for effective PEP to cover the window period for potential HIV integration and replication. *Tenofovir disoproxil fumarate + Emtricitabine + Raltegravir for 28 days* - This was the **previous standard PEP regimen** and is still an acceptable alternative if Dolutegravir is contraindicated or unavailable. - Raltegravir requires **twice-daily dosing** compared to Dolutegravir's once-daily regimen, which may affect adherence. - The 28-day duration is correct, but Raltegravir is no longer the first-line INSTI choice in current guidelines. *Single dose Tenofovir + Emtricitabine + Raltegravir* - A **single dose** of these medications is insufficient for **post-exposure prophylaxis (PEP)** as HIV replication needs to be suppressed over an extended period to prevent seroconversion. - PEP typically requires a **28-day course** to be effective. *Zidovudine + Lamivudine + Lopinavir/ritonavir for 28 days* - While this is an older, effective **antiretroviral regimen**, it is **not the preferred first-line PEP regimen** due to a higher incidence of side effects, particularly with zidovudine (anemia, nausea). - Modern guidelines favor regimens with **Tenofovir/Emtricitabine + Dolutegravir** due to better tolerability and superior efficacy.
Explanation: ***Correct Option: Chloroquine***- **Chloroquine** remains the **first-line treatment** for **chloroquine-sensitive P. vivax** infections due to its high efficacy and safety profile [1, 2].- It rapidly clears **blood-stage parasites**, alleviating acute symptoms of malaria [3].- In areas where P. vivax remains sensitive, chloroquine is preferred due to low cost, good tolerability, and proven effectiveness [1, 2].*Incorrect Option: Mefloquine*- **Mefloquine** is typically reserved for areas with **chloroquine-resistant P. falciparum** or for prophylaxis in such regions.- Its use is generally avoided when less toxic and equally effective options like chloroquine are available for sensitive strains.- Associated with more neuropsychiatric side effects.*Incorrect Option: Artesunate*- **Artesunate** is an **artemisinin derivative**, primarily used for severe malaria or in areas with **multi-drug resistant P. falciparum**.- While effective, it is not the preferred first-line agent for chloroquine-sensitive P. vivax due to the availability of simpler, equally effective treatments.- Typically used in combination therapy (ACT) for resistant strains.*Incorrect Option: Quinine*- **Quinine** is an older antimalarial, often used for **severe malaria** or in cases of **chloroquine-resistant P. falciparum**.- It has a higher incidence of side effects compared to chloroquine (cinchonism, hypoglycemia) and is not the preferred choice for chloroquine-sensitive P. vivax.- Requires longer treatment duration with more monitoring.
Explanation: ***Capsular polysaccharide with carrier*** - The Hib conjugate vaccine uses a **polysaccharide capsule** from *Haemophilus influenzae* type b (Hib) covalently linked to a **protein carrier** [1]. - This conjugation allows activated B cells to present the polysaccharide to T helper cells, inducing a strong **T-cell dependent immune response** and **immunological memory**, especially in infants [1]. *Capsular polysaccharide* - A vaccine made only of **capsular polysaccharide** would be a **polysaccharide vaccine**, which induces a **T-cell independent immune response**. - This type of vaccine is **poorly immunogenic in infants** and does not generate long-lasting memory. *Purified protein with carrier* - This describes components of some **protein subunit vaccines**, but not specifically the Hib vaccine, which targets the polysaccharide capsule. - While it employs a carrier protein, the primary antigen is the **polysaccharide**, not a purified bacterial protein. *Cell wall polysaccharide* - The Hib vaccine specifically targets the **capsular polysaccharide**, which is distinct from the general cell wall polysaccharides found in the bacterial outer membrane. - The **capsule** is the primary virulence factor and target for protective immunity in Hib.
Explanation: ***Acyclovir*** - **Acyclovir** is an antiviral medication specifically used to treat infections caused by **herpes viruses** (e.g., HSV, VZV), not influenza viruses. - It works by inhibiting **viral DNA polymerase**, a mechanism distinct from how anti-influenza drugs act. - **This drug has never been indicated for influenza** - it is the correct answer to this "not indicated" question. *Amantadine* - **Amantadine** is an M2 ion channel inhibitor that **was indicated** for influenza A treatment and prophylaxis. - Although no longer recommended due to widespread **resistance** among circulating influenza strains, it remains a drug that was formally indicated for seasonal influenza. *Rimantadine* - **Rimantadine** is also an M2 ion channel inhibitor, structurally related to amantadine, with a similar mechanism of action. - Like amantadine, it **was indicated** for influenza treatment or prophylaxis but is no longer recommended due to high rates of **resistance** in circulating influenza A viruses. *Oseltamivir* - **Oseltamivir** is a **neuraminidase inhibitor** currently approved and recommended for the treatment and prophylaxis of both influenza A and B. - It reduces viral spread by preventing the release of new virions from infected cells and remains a first-line agent for seasonal influenza.
Explanation: ***Given at birth*** - The **typhoid Vi polysaccharide vaccine is not administered at birth**. It is recommended for individuals **2 years of age**. - Vaccines given at birth protect against diseases with significant **neonatal risk**, such as Hepatitis B and BCG (tuberculosis). - This is the **FALSE** statement, making it the correct answer to this "not true" question. *Single dose is given* - The Vi polysaccharide vaccine is administered as a **single 0.5 mL dose**. - This single dose provides protection against *Salmonella typhi* for approximately 3 years. - This statement is **TRUE**. *Revaccination at 3 years* - For ongoing protection, **revaccination is recommended every 3 years** for individuals at continued risk of typhoid exposure. - The booster dose maintains adequate protective antibody levels. - This statement is **TRUE**. *Given intramuscularly* - The Vi polysaccharide vaccine is administered via the **intramuscular (IM) route**, typically in the deltoid muscle. - This is the standard recommended route of administration. - This statement is **TRUE**.
Explanation: ***All statements are correct.*** - Each of the preceding statements is factually accurate regarding influenza vaccines. - The **inactivated vaccine** is widely used, the **live attenuated vaccine** is administered via nasal spray, and the **inactivated vaccine** is given intramuscularly [1]. *The inactivated vaccine is used most commonly.* - The **inactivated influenza vaccine (IIV)**, given by injection, is the most frequently administered type of influenza vaccine. - It is recommended for most age groups and is safe for individuals with chronic medical conditions, pregnant women, and the elderly. *The live attenuated vaccine is given by nasal spray.* - The **live attenuated influenza vaccine (LAIV)**, also known as FluMist, is administered as a **nasal spray** [1]. - This vaccine is suitable for healthy individuals aged 2-49 years and is not recommended for pregnant women or individuals with certain immune compromising conditions. *The inactivated vaccine is given intramuscularly in the deltoid.* - The standard route of administration for the **inactivated influenza vaccine (IIV)** is via **intramuscular injection**, most commonly into the **deltoid muscle** in adults and older children [1]. - This method ensures proper absorption and an effective immune response, a common practice for many vaccines.
Explanation: ***Correct: Erythrocytic*** - Quinine primarily acts as a **blood schizonticide**, targeting the asexual erythrocytic stages of the *Plasmodium* parasite. - Its mechanism involves interfering with the parasite's ability to detoxify **heme**, leading to accumulation of toxic byproducts and parasite death within **red blood cells**. - This is why quinine is effective in treating **acute malaria attacks** during the symptomatic phase of the disease. *Incorrect: Exoerythrocytic* - The **exoerythrocytic stage** occurs in the liver, where sporozoites develop into merozoites. - Quinine has **minimal or no activity** against these liver stages, meaning it does not prevent initial infection or relapse from hepatic dormant forms (hypnozoites). - Drugs like **primaquine** target this stage. *Incorrect: Pre-erythrocytic* - The **pre-erythrocytic stage** is another term for the exoerythrocytic or liver stage of the parasite life cycle, occurring before the parasite enters red blood cells. - Medications that target this stage are known as **causal prophylactics**, which quinine is not. - Quinine has **no significant activity** at this stage. *Incorrect: None of the options* - This option is incorrect as quinine specifically targets the **erythrocytic stage**, making that option the correct answer. - Quinine's effectiveness in treating malaria stems from its action during the **symptomatic phase** of the disease, which corresponds to the erythrocytic cycle in red blood cells.
Explanation: ***Isoniazid (INH)*** - **Isoniazid** renders TB patients **non-infectious the fastest**, typically within **2-3 days** of starting treatment - It has the most **rapid bactericidal effect** against actively multiplying extracellular **Mycobacterium tuberculosis**, which are the primary organisms responsible for transmission - INH works by inhibiting **mycolic acid synthesis**, disrupting the bacterial cell wall of rapidly dividing bacilli - This makes it the most critical drug for **early infection control** and reducing community transmission *Rifampin* - While **rifampin** is highly bactericidal and has excellent sterilizing activity, it takes **slightly longer** than INH to render patients non-infectious - Rifampin is particularly effective against **semi-dormant organisms** and intracellular bacilli - It is the most important drug for **preventing relapse** and shortening treatment duration, but INH acts faster in reducing infectivity *Ethambutol* - **Ethambutol** is primarily **bacteriostatic**, inhibiting arabinosyl transferase and interfering with cell wall synthesis - Its main role is to **prevent emergence of drug resistance** rather than rapidly reducing bacterial load - Has minimal impact on early infectivity reduction *Pyrazinamide* - **Pyrazinamide** is most effective against **semi-dormant bacilli** within macrophages and in acidic environments - Its **sterilizing activity** helps shorten overall treatment duration but does not contribute significantly to rapid reduction in infectivity - Works slowly and is not bactericidal against actively multiplying extracellular organisms
Explanation: ***Sulfonamide*** - **Thymidine** can contribute to **sulfonamide resistance** because sulfonamides interfere with **folate metabolism** and the subsequent synthesis of purines and pyrimidines, including thymidine. - An excess of thymidine can bypass the metabolic block caused by sulfonamides, allowing bacteria to continue DNA synthesis and grow. *Erythromycin* - **Erythromycin** resistance is primarily mediated by **methylation of ribosomal RNA**, which prevents the antibiotic from binding to the 50S ribosomal subunit. - It does not directly involve thymidine or the folate synthesis pathway. *Tetracycline* - Resistance to **tetracyclines** is commonly due to **efflux pumps** that actively pump the drug out of the bacterial cell or **ribosomal protection proteins** that prevent tetracycline binding. - Thymidine production or metabolism is not a mechanism of tetracycline resistance. *Nitrofurantoin* - **Nitrofurantoin** resistance typically involves **mutations** in bacterial enzymes (like **nitrofuran reductase**) that are responsible for activating the drug into its active form. - These mutations prevent the drug from becoming bactericidal, and thymidine does not play a role in this mechanism.
Beta-Lactam Antibiotics
Practice Questions
Aminoglycosides
Practice Questions
Macrolides and Ketolides
Practice Questions
Tetracyclines
Practice Questions
Quinolones
Practice Questions
Sulfonamides and Trimethoprim
Practice Questions
Antimycobacterial Drugs
Practice Questions
Antifungal Agents
Practice Questions
Antiviral Drugs
Practice Questions
Antiparasitic Agents
Practice Questions
Principles of Antimicrobial Selection
Practice Questions
Antimicrobial Resistance
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free